Toro Neurovascular Achieves FDA Approval: A New Era in Stroke Treatment

In an important milestone for the medical device industry, Toro Neurovascular has announced it has secured its first major regulatory approval from the FDA for its Toro 88 Superbore Catheter. This breakthrough, aimed specifically at treating acute ischemic strokes, comes amidst growing concern about neurovascular conditions and their impact on patients’ quality of life. Based in Irvine, California, Toro Neurovascular is setting a new standard in high-performance catheters, showcasing innovation rooted in purposeful engineering and collaboration with medical professionals.

Partnership with Kaneka Medical and Market Strategy

Following the FDA clearance, Toro Neurovascular has partnered with Kaneka Medical America LLC, a subsidiary of the Japanese manufacturing giant Kaneka Corp. This exclusive partnership will spearhead the U.S. launch of the Toro 88 catheter, marking a strategic move towards expanding market reach and product portfolios. With a phased rollout strategy in place, the companies aim to introduce additional products over time, indicating a long-term vision for growth and innovation within the neurovascular device sector.

To further strengthen its commercialization efforts, Toro has appointed Marc Paris as its Chief Commercial Officer. With over two decades of experience in medical device commercialization, Paris is expected to play a pivotal role in coordinating launch strategies in tandem with Kaneka. His leadership will help ensure that the Toro 88 catheter reaches healthcare providers and, ultimately, patients who can benefit from this cutting-edge technology.

Innovative Design Features of the Toro 88 Catheter

The Toro 88 Superbore Catheter has been engineered with a wide internal diameter, a feature that enhances its capability to effectively remove blood clots. Clinical data suggests that patients treated with large-bore catheters experience a significantly higher first-pass effect, which translates into shorter procedure times and potentially better outcomes. The catheter is equipped with MicroFlex technology, incorporating reinforced wires that provide flexibility in navigating complex neurovascular anatomy, which can be critical during acute interventions.

Dr. Satoshi Tateshima, a prominent interventional neuroradiologist at UCLA and one of the first to clinically use the Toro 88 in the United States, expressed enthusiasm over its performance. His experience in the catheter’s development impressed him during the initial clinical applications, marking a significant step forward in technology that could improve patient results in acute stroke care.

Positive Clinical Trial Results

The inaugural clinical trial for the Toro 88 Catheter was conducted in Japan in 2024, involving a cohort of 15 patients. Results gathered from this trial were presented in late 2025, revealing a remarkable success rate. The device achieved 100% successful delivery with no serious adverse events related to its use—a result that highlights both the safety and efficacy of the Toro 88 in a clinical setting. These findings not only validate the technological advancements made by Toro Neurovascular but also pave the way for widespread adoption in emergency medical treatment protocols.

Understanding the Significance of Ischemic Strokes

The urgency behind developing cutting-edge devices like the Toro 88 cannot be overstated. Stroke continues to be a leading cause of death and disability worldwide, with the National Institutes of Health reporting over 795,000 instances of stroke occurring each year in the United States alone. Most of these cases involve first-time or new strokes. With growing awareness of the life-altering consequences of strokes, the need for effective and rapid treatments is critical, making innovations such as the Toro 88 increasingly vital for healthcare providers.

The Founders’ Vision for Toro Neurovascular

Founded in 2021, Toro Neurovascular was initiated by Hyung Posalit and Ryan Walker, who both share a passion for revolutionizing treatment options in ischemic strokes. Their prior experience at NeuroVasc Technologies Inc. positions them uniquely to lead Toro’s mission. Posalit brings an engineering background from UC Irvine, having contributed to multiple medical device startups prior to founding Toro. Walker, the Chief Operating Officer, complements Posalit’s expertise, focusing on pushing the boundaries of neurovascular devices and improving patient outcomes through innovation.

Conclusion

Toro Neurovascular’s achievement of FDA clearance for the Toro 88 Superbore Catheter represents a significant advancement in the realm of neurovascular treatments, particularly for ischemic stroke patients. The partnership with Kaneka Medical America enhances the distribution efforts and market strategies necessary to ensure the success of this groundbreaking device. As clinical trials demonstrate its efficacy and safety, the Toro 88 is poised to set a new standard for high-performance catheters in the medical device industry. With seasoned leadership and a focus on innovation, Toro Neurovascular is ready to lead the charge in improving treatment options for one of the most pressing health challenges of our time.